Evidence map›Paper›PMID 39931368›Full record

ArticleFrontiers in nutrition2025

Burden of NASH related liver cancer from 1990 to 2021 at the global, regional, and national levels.

Shuang Li, Shuangjiang Li, Linjing Guan, Mingjuan Li, Jiahui Zhao, Min Wu, Qiuyun Li, Hui Li, Guoqing Ouyang, Guangdong Pan

Abstract read
In one paragraph

Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Novel Therapeutics for Hepatocellular Carcinoma.Clinics in liver disease · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuang Li *Graduate School of Guangxi University of Chinese Medicine, Nanning, Guangxi, China.
Shuangjiang Li *Department of General Surgery, Liuzhou People's Hospital, Liuzhou, Guangxi, China.
Linjing Guan *Department of Abdomen Ultrasound, Nanning Sixth People's Hospital, Nanning, Guangxi, China.
Mingjuan LiDepartment of General Surgery, Liuzhou People's Hospital, Liuzhou, Guangxi, China.
Jiahui ZhaoDepartment of General Surgery, Liuzhou People's Hospital, Liuzhou, Guangxi, China.
Min WuDepartment of General Surgery, Liuzhou People's Hospital, Liuzhou, Guangxi, China.
Qiuyun LiDepartment of General Surgery, Liuzhou People's Hospital, Liuzhou, Guangxi, China.
Hui LiDepartment of Respiratory Medicine, The First Hospital of Changsha, Changsha, Hunan, China.
Guoqing OuyangDepartment of General Surgery, Liuzhou People's Hospital, Liuzhou, Guangxi, China.
Guangdong PanGraduate School of Guangxi University of Chinese Medicine, Nanning, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The global burden of non-alcoholic steatohepatitis (NASH)-related liver cancer (NRLC) is increasing, making NASH the fastest-growing cause of liver cancer worldwide. This study presents a comprehensive analysis of NRLC burden at the global, regional, and national levels, further categorized by age, sex, and sociodemographic index (SDI). Method: Data on NRLC from the Global Burden of Disease, Injuries, and Risk Factors (GBD) study 2021 were downloaded at global, regional, and national levels. The numbers and age-standardized rates (ASRs) of incidence, mortality, and disability-adjusted life years (DALYs) were analyzed to quantify the global burden of NRLC. Additionally, percentage changes in ASRs were used to identify trends in NRLC from 1990 to 2021. Results: Globally, both the number of cases and ASRs for NRLC increased between 1990 and 2021. In 2021, there were 42,291 new cases, 40,925 deaths, and 995,475 DALYs attributed to NRLC. East Asia, South Asia, and Southeast Asia reported the highest absolute case numbers, while Western, Southern, and Eastern Sub-Saharan Africa exhibited the highest ASRs. From 1990 to 2021, Australasia, Southern Latin America, and High-income North America showed the most significant increases in NRLC incidence. Nationally, Mongolia, Gambia, and Mozambique exhibited the highest ASR in 2021.The greatest percentage increases in ASIR occurred in Australia, the United Kingdom, and New Zealand between 1990 and 2021. NRLC incidence rates were higher in men and increased with age, peaking at 80-89 years. Similar patterns were observed for NRLC-related deaths and DALYs. Regionally, ASRs initially declined but then increased as SDI rose. At the national level, ASRs consistently decreased with higher SDI. Conclusion: This study highlights the substantial burden of NRLC at global, regional, and national levels. Males and older individuals bear a higher disease burden, and considerable variation exists across different regions and countries. These findings provide critical insights for formulating effective strategies to prevent and manage NRLC.

Indexed as

age-standardized ratedeathdisability-adjusted life yearsincidenceNASH-related liver cancer

Identifiers

PMID39931368
PMCPMC11807830

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.